Separate names with a comma.
Discussion in 'Genentech' started by anonymous, May 31, 2017 at 6:23 AM.
It's a great place to be.
It seems there are a lot of changes taking place all to quickly, what's up with that?
DYING franchise. Heck had big RIF right before the NSM LV bash in Jan 2016. Worst enemy is the heck of lot cheaper (and as safe) diluted Avastin. Just wait till Avastin biosimilars from big pharmas hit the market soon as it will be death kneel to Retina reps.
I call bullcrap. At best, the biosimilar will be 75% of the price
Here's some news for ya. LOL troll as it WON'T be 75% but more like 50% based on what's happening in EU.
And yeah what's deal with declining sales from $4 to $3.5 bil?
This franchise has a bright future. Genentech supports ophthalmology and will continue to invest. More indications than competitor. Great place to be!
it is a great place to be ......and your welcome. -A
Just got a call from a recruiter for a possible opening or expansion later this year but no details. What's the story?
no story, either an open territory or nothing else
My understanding was that it was for a new drug, possibly lampalizumab?
With the lampalizumab trial not meeting primary endpoint, what is the future of this franchise?
Get by till Avastin biosims become viable alternate then jump ship.
Uh oh - Genentech partner Samsung is working even on Lucentis biosim in addition to Avastin, Herceptin and Rituxan. Kimchee lovers learned how to make Rituxan from DNA, turned around and copied it.